TERUMO (4543) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Terumo delivered an increase in both revenue and profit, accompanied by growth rates, while profitability also improved from the previous year. Revenue was ¥8,315.6B (+7.7% year on year), Operating Income was ¥1,448.7B (+8.5%), Profit Before Tax was ¥1,465.9B (+11.2%), and quarterly Net Income attributable to owners of the parent was ¥1,095.5B (+11.1%). Profit growth exceeded revenue growth, and the Operating Income margin improved to 17.4% (17.3% in the previous year). Growth in revenue and profit at the Blood and Cell Technologies Company, together with the consolidation contribution from the acquisition of OrganOx as a wholly owned subsidiary, served as the primary drivers. However, nonrecurring gains and losses, including acquisition-related expenses and impairment losses, reduced reported profit.

Factors Affecting Business Performance

【Revenue】Revenue increased 7.7% year on year to ¥8,315.6B. By segment, the Cardiovascular Company was the largest and primary earnings contributor, with revenue of ¥4,967.6B (59.8% of the total, +7.0% year on year). The Blood and Cell Technologies Company recorded revenue of ¥1,685.3B (20.3% of the total, +13.8%), representing the highest growth rate. The Medical Care Solutions Company recorded revenue of ¥1,631.8B (19.6% of the total, +2.2%), indicating comparatively slower growth. OrganOx, which became a wholly owned subsidiary in October 2025, newly contributed ¥28.5B to consolidated revenue.

【Profitability】Operating Income was ¥1,448.7B (+8.5% year on year). The gross margin declined to 53.6% from 54.7% in the previous year, but the Operating Income margin improved to 17.4% as the SG&A expense ratio was kept nearly flat at 35.5%. Amortization of acquired intangible assets of ¥171.2B and nonrecurring gains and losses of △¥114.8B, including business restructuring expenses, impairment losses of ¥47.7B, and acquisition-related expenses, reduced reported Operating Income. Excluding these items, adjusted Operating Income was ¥1,734.7B (+10.5%), indicating solid underlying earnings power. The conversion rate from Profit Before Tax to Net Income was also favorable, leading to the conclusion that the company delivered an increase in both revenue and profit.

Segment Analysis

The Cardiovascular Company is the core contributor to company-wide profit, with revenue of ¥4,967.6B (59.8% of the total), Operating Income of ¥1,293.4B, and a profit margin of 26.0%. The Blood and Cell Technologies Company recorded revenue of ¥1,685.3B and a profit margin of 15.0%, with its profit margin improving significantly from the previous year, indicating simultaneous progress in revenue growth and profitability improvement. The Medical Care Solutions Company recorded revenue of ¥1,631.8B and a profit margin of 12.1%, making it comparatively less profitable, while its growth pace was also moderate. The newly established OrganOx segment recorded revenue of ¥28.5B and a profit margin of 18.1%, beginning to contribute to consolidated profit at the early stage following the acquisition. The gap in profit margins between segments reached approximately 14pt at its widest, confirming that the Cardiovascular area remains the center of the earnings mix.

Key Financial Metrics

【Profitability】The Operating Income margin of 17.4% (17.3% in the previous year) and Net Income margin of 13.2% (12.8% in the previous year) both improved from the previous year. Although the gross margin declined to 53.6% from 54.7%, the Operating Income margin improved because SG&A expenses grew by +5.0%, below revenue growth of +7.7%. 【Cash Quality】Operating Cash Flow (OCF) was ¥1,419.4B, equivalent to 1.30 times Net Income, indicating strong cash backing for earnings. 【Investment Efficiency】ROE was 7.2%; the low total asset turnover ratio is a constraint on capital efficiency relative to the high Net Income margin. 【Financial Soundness】The Equity Ratio was 67.5%. Current assets of ¥8,155.6B versus current liabilities of ¥5,397.0B resulted in a current ratio of approximately 151%, indicating that the company maintained a conservative financial base even after major investments.

Cash Flow Analysis

Operating Cash Flow was ¥1,419.4B, nearly flat at -1.6% year on year. This amount was calculated by deducting income taxes paid of ¥390.5B, interest paid of ¥18.8B, and other items from operating cash flow subtotal of ¥1,798.1B; working capital placed pressure on cash, primarily due to increases of ¥243.5B in trade receivables and ¥108.5B in inventories. Investing Cash Flow was an outflow of ¥3,157.4B, primarily due to acquisitions and investments, including the acquisition of OrganOx as a wholly owned subsidiary, and was substantially larger than ordinary capital expenditures of ¥500.4B. As a result, Free Cash Flow was negative ¥1,738.1B. However, Financing Cash Flow was positive at ¥1,776.3B, with financing through bonds and borrowings offsetting the investment excess. Cash and cash equivalents increased to ¥2,380.0B, while cash generation from ordinary business activities—approximately ¥918.9B after deducting capital expenditures from Operating Cash Flow—was sufficient to cover dividend payments of ¥412.4B.

Earnings Quality

Against reported Operating Income of ¥1,448.7B, adjusted Operating Income after adjusting for amortization of acquired intangible assets of ¥171.2B and nonrecurring gains and losses of △¥114.8B, including business restructuring expenses, impairment losses, and acquisition-related expenses, was ¥1,734.7B, with an adjusted Operating Income margin of 20.9%. Recurring business earnings power is therefore stronger than indicated by the reported figures. Financial income of ¥41.1B exceeded financial expenses of ¥17.6B, with nonoperating income and expenses contributing positively to profit. Operating Cash Flow was 1.30 times Net Income, indicating strong cash backing for earnings. However, increases in trade receivables and inventories placed pressure on working capital, and from an accruals perspective, trends in inventory and receivables turnover should be monitored continuously.

Earnings Forecast and Guidance

Progress against the full-year forecast was 75.1% for revenue (¥8,315.6B / ¥1,108.0B), 79.8% for Operating Income (¥1,448.7B / ¥1,815.0B), and 80.5% for Net Income (¥1,095.5B / ¥1,360B). Revenue progress was in line with the standard 75% level, while profit progress exceeded this level, with improved profitability driving progress above plan. To achieve the full-year forecast, Q4 Operating Income would need to increase by approximately 51% year on year, making the maintenance of existing business margins and expansion of OrganOx’s contribution key areas of focus. The earnings forecast and dividend forecast (¥30.00 per share) were both unchanged.

Shareholder Returns

The Q2 dividend of ¥15.00 per share has been paid, and the full-year dividend forecast remains unchanged at ¥30.00 per share. The forecast Payout Ratio calculated based on the full-year Net Income forecast of ¥1,360B and the average number of shares outstanding during the period is approximately 32.5%, remaining below 60%. Share repurchases were minimal at ¥0.01B, resulting in a Total Return Ratio approximately equal to the Payout Ratio. Approximately ¥918.9B, representing Operating Cash Flow less capital expenditures, was about 2.2 times dividend payments of ¥412.4B, indicating favorable dividend coverage from ordinary operating cash flow. On the other hand, Free Cash Flow was negative due to investment activities, including the acquisition of OrganOx, indicating that capital allocation during the period prioritized growth investments.

Risk Factors

1. Prolonged working capital cycle: Trade receivables increased +20.7% from the beginning of the period, while inventories increased +14.6%; both grew faster than the revenue growth rate of +7.7%. A prolonged collection and inventory turnover cycle could constrain upside in Operating Cash Flow, and future improvement should be closely monitored.

2. OrganOx integration and goodwill impairment risk: Following the acquisition of OrganOx as a wholly owned subsidiary, goodwill and intangible assets increased by ¥2,552.6B (+46.8%) from the beginning of the period, accounting for 35.5% of total assets. If integration progress or expected synergies fail to materialize, future impairment risk will increase.

3. Nonrecurring gains and losses and acquisition-related expenses: During the period, nonrecurring gains and losses of △¥114.8B, including business restructuring expenses, impairment losses of ¥47.7B, and acquisition-related expenses, reduced reported Operating Income. If the acquisition and restructuring phase continues, the persistence of volatility in reported profit is an important consideration when assessing earnings quality.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Income margin and Net Income margin substantially exceeded the industry median, placing profitability in the upper tier of the industry.

Growth and Capital Efficiency

The revenue growth rate also exceeded the industry median, indicating that the company is competitively positioned within the industry in both profitability and growth.

Source: Compiled by the Company

Key Earnings Highlights

1. High profitability and strong cash backing for earnings: The Operating Income margin of 17.4% and Net Income margin of 13.2% substantially exceeded the industry median, while Operating Cash Flow was 1.30 times Net Income, indicating favorable earnings quality. The adjusted Operating Income margin of 20.9% demonstrates strong underlying business earnings power.

2. Financial soundness maintained after major investments: With an Equity Ratio of 67.5% and a current ratio of approximately 151%, the company maintained a conservative financial base even after the large-scale investment associated with the acquisition of OrganOx as a wholly owned subsidiary.

3. Working capital and goodwill trends: Trade receivables and inventories are increasing faster than revenue, indicating room to improve turnover efficiency from a cash generation perspective. The fact that goodwill and intangible assets account for 35.5% of total assets is an important point of observation when evaluating future integration progress.

Theoretical Stock Price (Reference Value)

Sensitivity: ¥1,000–¥1,059 at a ±1% change in the Cost of Equity, and ¥1,029–¥1,029 at a ±0.1 change in ω.

Notes:

• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market stock price or a recommendation of any specific investment action, and does not predict or guarantee the future stock price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Terumo delivered a solid FY2026 Q3 cumulative earnings result, with revenue, operating income, and net income all growing faster than the prior-year period. Revenue increased 7.7% year on year to ¥831.6bn. Operating income rose 8.5% to ¥144.9bn, while net income attributable to owners increased 11.1% to ¥109.5bn. The reported operating margin improved modestly by 13bp to 17.4%. Net margin expanded by 40bp to 13.2%, supported by lower net finance costs as finance income increased to ¥4.1bn and finance costs declined to ¥1.8bn. Gross margin, however, contracted by 108bp to 53.6%, indicating that product mix, manufacturing costs, or pricing effects partly offset the benefit of sales growth. SG&A increased 5.0%, below revenue growth, creating positive operating leverage. On the company’s adjusted basis, segment profit increased to ¥173.5bn and the adjusted operating margin rose by approximately 23bp to 20.9%. The core Cardiovascular Company remained the largest earnings contributor, generating ¥496.8bn of sales and ¥129.3bn of adjusted operating profit. Blood and Cell Technologies was the strongest major segment on a profit-growth basis, with segment profit rising 27.4%. Cash earnings conversion was sound, as operating cash flow of ¥141.9bn exceeded net income by 1.30x. Nevertheless, receivables, inventories, and payables collectively consumed cash, and the cash conversion cycle of 241 days is a material operational issue. Reported free cash flow was negative ¥173.8bn because investing cash outflow reached ¥315.7bn, principally reflecting acquisition-related investment. The October 2025 acquisition of OrganOx materially enlarged goodwill and intangible assets and was financed substantially with new borrowings, shifting the balance sheet toward greater acquisition-related leverage. Management maintained full-year guidance, and Q3 progress is slightly ahead of a straight-line pace for operating profit and net income. The key forward issue is whether OrganOx integration, the enlarged intangible asset base, and elevated working-capital intensity can be managed without diluting Terumo’s historically strong profitability and cash conversion.

Profitability Analysis

Annualized DuPont ROE is 9.6%, comprising a 13.2% net profit margin, 0.491x asset turnover, and 1.48x financial leverage. The principal support for ROE is the high net margin rather than aggressive leverage, although asset turnover is restrained by the enlarged asset base following the OrganOx acquisition. The reported operating margin improved to 17.4% from 17.3%, while net margin rose to 13.2% from 12.8%. Gross margin declined to 53.6% from 54.7%, a 108bp contraction, but SG&A grew only 5.0% against 7.7% revenue growth, more than offsetting gross-margin pressure at the operating-profit level. The tax burden was 0.747 and the interest burden was 1.012, indicating a normal effective tax rate and a net positive finance-income contribution to pre-tax profit. The adjusted operating-profit measure increased 8.9% to ¥173.5bn; adjusted operating margin was approximately 20.9%, up 23bp year on year. Cardiovascular is the core business, contributing ¥496.8bn of revenue and ¥129.3bn of adjusted operating profit, with its segment margin improving to 26.0% from 25.4%. Medical Care Solutions generated ¥163.2bn of revenue and ¥19.7bn of segment profit, with a broadly stable 12.1% margin. Blood and Cell Technologies generated ¥168.5bn of revenue and ¥25.2bn of segment profit; its margin expanded materially to 15.0% from 13.4%. OrganOx contributed ¥2.9bn of revenue and ¥0.5bn of segment profit following consolidation from Q3, implying an 18.1% segment margin but based on a short consolidation period. Reported operating profit includes ¥11.5bn of one-time costs, comprising ¥4.8bn of impairment, ¥3.4bn of associated costs, and ¥3.3bn of acquisition-related costs. Acquired-intangible amortization was ¥17.1bn, which is economically relevant for assessing post-M&A earnings capacity under IFRS even though it is excluded from management’s adjusted-profit KPI. Margin resilience is constructive, but sustainability depends on preserving gross-margin discipline and realizing acquisition synergies while avoiding further integration-related charges.

Growth Assessment

Growth was broad-based across the established operating segments. Cardiovascular revenue increased 7.0% and adjusted operating profit increased 9.7%, demonstrating continued scale-led earnings growth in the group’s largest franchise. Medical Care Solutions revenue increased 2.2% and segment profit increased 2.7%, representing steadier but more moderate growth. Blood and Cell Technologies revenue increased 13.8% and segment profit increased 27.4%, making it the most important source of incremental segment earnings and margin expansion. OrganOx added a new organ-preservation business platform from Q3, strengthening exposure to specialized transplant technologies. Reported operating income growth of 8.5% exceeded revenue growth of 7.7%, and net income growth of 11.1% was stronger still, evidencing favorable operating leverage and finance-cost improvement. Full-year guidance calls for revenue of ¥1,108.0bn, operating income of ¥181.5bn, and net income of ¥136.0bn. Q3 cumulative progress is 75.1% for revenue, 79.8% for operating income, and 80.5% for net income, versus a standard 75% progress rate. Operating-income and net-income progress are ahead of the standard pace by 4.8 percentage points and 5.5 percentage points, respectively, but neither deviation exceeds the 10 percentage-point threshold. Achievement of guidance therefore requires a comparatively lower Q4 operating margin than achieved cumulatively, which is plausible given acquisition integration costs and normal quarterly seasonality. Growth quality is supported by operating cash flow exceeding net income, but balance-sheet growth has been disproportionately driven by M&A: total assets increased ¥428.5bn from FY2025 year-end, including a ¥255.3bn increase in goodwill and intangible assets. The sustainability of growth should therefore be assessed not only through reported revenue expansion but also through OrganOx revenue scaling, integration execution, and returns on the acquired asset base.

Financial Health

Financial health remains underpinned by a high 67.5% equity ratio and ¥1,522.3bn of total equity. The current ratio is 1.51x, based on current assets of ¥815.6bn and current liabilities of ¥539.7bn, meeting the 1.5x healthy benchmark and not indicating a current-ratio warning. Current assets exceed current liabilities by ¥275.9bn, providing a positive liquidity buffer. Cash and cash equivalents were ¥238.0bn at the quarter end. Total liabilities increased to ¥734.6bn from ¥459.9bn at FY2025 year-end, principally as the acquisition was funded through borrowings. Bonds and borrowings totaled ¥399.7bn, comprising ¥299.8bn current and ¥99.9bn non-current. The current portion of bonds and borrowings increased sharply from ¥15.0bn at FY2025 year-end, while non-current borrowings declined from ¥159.8bn, indicating a substantial increase in near-term refinancing or repayment requirements. Although the current ratio remains healthy, the concentration of borrowings in current liabilities heightens maturity-management risk. Debt-to-equity of 0.48x remains below the 1.0x conservative benchmark and well below the 2.0x explicit warning threshold. Interest costs were only ¥1.8bn against operating income of ¥144.9bn, indicating very strong interest-servicing capacity. Goodwill and intangible assets were ¥800.5bn, equal to 35.5% of total assets and 52.6% of equity; this makes balance-sheet value increasingly dependent on the performance of acquired businesses and associated impairment testing. Other comprehensive income was ¥85.3bn, primarily ¥85.8bn of foreign-currency translation gains, which supported equity but also signals meaningful foreign-currency translation exposure.

Notable B/S Changes

Goodwill and intangible assets: +¥255.3bn (+46.8%) to ¥800.5bn - OrganOx acquisition materially increased M&A-related asset concentration; impairment-test performance and integration returns are key. Total assets: +¥428.5bn (+23.4%) to ¥2,256.9bn - balance-sheet expansion was led by acquired intangibles, PPE, and working-capital growth. Bonds and borrowings, current: +¥284.8bn to ¥299.8bn - acquisition financing materially increased short-term funding and refinancing requirements. Bonds and borrowings, non-current: -¥59.9bn (-37.5%) to ¥99.9bn - debt maturity composition shifted markedly toward current liabilities. Total liabilities: +¥274.8bn (+59.8%) to ¥734.6bn - leverage increased in connection with acquisition financing, though the equity ratio remained a solid 67.5%. Inventories: +¥43.1bn (+14.7%) to ¥337.5bn - inventory growth exceeded the increase in receivables in absolute terms and accompanies a high 239-day DIO, increasing cash-lockup and inventory-quality risk. Accounts receivable: +¥36.6bn (+20.7%) to ¥213.5bn - receivable growth and 70-day DSO indicate slower collection and contribute to the long cash conversion cycle. Property, plant and equipment: +¥63.2bn (+14.7%) to ¥494.2bn - supports continuing manufacturing investment, with capital expenditure of ¥50.0bn during the nine-month period. Total equity: +¥153.8bn (+11.2%) to ¥1,522.3bn - retained earnings growth and ¥85.3bn of OCI, mainly foreign-currency translation gains, offset owner distributions.

Cash Flow Quality

Cash-flow quality is favorable at the earnings-conversion level: operating cash flow was ¥141.9bn, equivalent to 1.30x net income of ¥109.5bn. This exceeds the 1.0x high-quality benchmark and is consistent with the negative 1.4% accruals ratio. Operating cash generation nevertheless declined modestly from ¥144.3bn in the prior-year period despite higher net income, because working capital absorbed cash. Receivables increased by ¥24.3bn, inventories increased by ¥10.8bn, and payables decreased by ¥7.8bn, resulting in a combined working-capital cash outflow of approximately ¥43.0bn before other changes. The DSO quality alert is material: receivable days of 70 exceed the 60-day warning threshold and point to slower cash collection or a less favorable sales and customer mix. Inventory days of 239 are substantially above both the 90-day general warning threshold and the 60-day manufacturing benchmark. The inventory alert is particularly important for a medical-device manufacturer because prolonged inventory holding raises risks around demand forecasting, product expiry, product mix, and eventual write-downs. The 241-day cash conversion cycle is materially above the 120-day warning threshold, reflecting the combined pressure from high receivable and inventory days. This long cycle reduces the immediate cash yield of accounting earnings and should be monitored alongside future inventory provisioning. Capital expenditure was ¥50.0bn, or approximately 6.0% of cumulative revenue, consistent with ongoing manufacturing and capacity investment. Operating cash flow less capital expenditure was positive ¥91.9bn, indicating that the underlying business funded ordinary capital investment. Reported free cash flow was negative ¥173.8bn because total investing cash outflow was ¥315.7bn, far exceeding ordinary capital expenditure and consistent with acquisition spending. Dividends of ¥41.2bn were covered about 2.2x by operating cash flow and about 2.2x by pre-acquisition free cash flow, but were not covered by reported free cash flow during the acquisition-heavy period.

Dividend Sustainability

The indicated full-year dividend is ¥30.0 per share, comprising the ¥15.0 interim dividend and an implied ¥15.0 year-end dividend. Based on full-year EPS guidance of ¥92.2, the prospective dividend payout ratio is approximately 32.5%. This is comfortably below the 60% sustainability benchmark and leaves substantial earnings retention capacity. The calculated Q2-only payout ratio against Q3 cumulative earnings is 20.3%, though the prospective full-year payout ratio is more informative for capital-allocation assessment. Cash dividends paid during the first nine months were ¥41.2bn, compared with operating cash flow of ¥141.9bn. Ordinary operating cash flow therefore provides adequate dividend coverage. Capital expenditure of ¥50.0bn also remained covered by operating cash flow, leaving approximately ¥91.9bn before acquisition-related investing activities. Reported free cash flow was negative ¥173.8bn and thus did not cover dividends in the period, but this reflects exceptional acquisition investment rather than a shortfall in underlying operational cash generation. Share repurchases were immaterial at ¥0.01bn, so the total return ratio is effectively equivalent to the dividend payout ratio in this period. The main constraint on future dividend flexibility is not the stated payout ratio but the increased borrowings and integration needs associated with OrganOx. Provided operating cash conversion normalizes and the acquisition performs to plan, the current dividend level appears sustainable on the available financial data.

Risk Assessment

Business risks include Working-capital efficiency risk: DSO of 70 days, DIO of 239 days, and a 241-day cash conversion cycle indicate slow conversion of revenue into cash. For a medical-device manufacturer, elevated inventories increase exposure to demand changes, expiry management, inventory obsolescence, and additional write-down risk., M&A integration risk: OrganOx was newly consolidated in Q3 and acquisition-related costs were ¥3.3bn. The acquisition has materially expanded the intangible asset base, making synergy realization, sales-force integration, regulatory execution, and retained product growth central to returns., Medical-device regulatory and quality risk: European MDR preparation costs were ¥1.3bn in the period. Regulatory compliance requirements, product approvals, clinical evidence, and post-market surveillance can raise costs or delay commercialization., Foreign-exchange risk: foreign-currency translation gains accounted for ¥85.8bn of the ¥85.3bn of other comprehensive income, highlighting sensitivity of reported equity and overseas asset values to currency movements., Margin risk: gross margin declined 108bp despite sales growth. Persistent input-cost, production-efficiency, product-mix, reimbursement, or pricing pressure could limit further operating-margin expansion..

Financial risks include Refinancing and maturity risk increased as current bonds and borrowings rose to ¥299.8bn from ¥15.0bn at FY2025 year-end. The current ratio remains 1.51x, but a large portion of acquisition financing is now short-term., Acquisition-related asset concentration risk is elevated: goodwill and intangible assets rose ¥255.3bn to ¥800.5bn, representing 35.5% of total assets and 52.6% of equity. Under IFRS, this creates material future impairment-test sensitivity if acquired business performance disappoints., Reported free cash flow was negative ¥173.8bn due to ¥315.7bn of investing outflows. Repeated acquisition-scale investment without commensurate operating cash growth could pressure leverage and capital-allocation flexibility., Debt-to-equity of 0.48x remains conservative and interest costs are low, mitigating near-term solvency risk despite the higher debt balance..

Key concerns include Highest priority: normalize the 241-day cash conversion cycle through improved receivable collection and inventory discipline., High priority: demonstrate that OrganOx can generate sufficient revenue growth and cash returns to justify the increase in intangible assets and acquisition financing., High priority: manage the ¥299.8bn current borrowing balance through refinancing, repayment, or sustained cash generation., Medium priority: contain recurring regulatory-compliance, impairment-related, and acquisition-related charges so that adjusted earnings translate into reported earnings..

Investment Implications

Key takeaways include Revenue grew 7.7%, operating income 8.5%, and net income 11.1%, with reported operating-margin expansion and a 40bp improvement in net margin., Cardiovascular remains the earnings engine, while Blood and Cell Technologies supplied the strongest major-segment revenue, profit, and margin growth., Operating cash flow exceeded net income by 1.30x, supporting the quality of core earnings., The acquisition of OrganOx has transformed the near-term financial profile through substantially higher intangibles, higher borrowings, and negative reported free cash flow., Full-year guidance is maintained, and Q3 cumulative operating-income and net-income progress are moderately ahead of a straight-line 75% pace., The operational counterweight to solid earnings is the unusually long 241-day cash conversion cycle, driven by 70-day receivables and 239-day inventory days..

Metrics to watch include OrganOx revenue, segment profit, integration costs, and the pace of acquisition-synergy realization, Goodwill and intangible assets relative to equity, impairment charges, and acquired-intangible amortization, Current bonds and borrowings of ¥299.8bn and the refinancing or repayment plan, DSO, DIO, cash conversion cycle, inventory adjustments, and operating cash flow conversion, Gross-margin recovery versus SG&A discipline and reported versus adjusted operating-profit conversion, Q4 revenue, operating-income, and net-income delivery relative to full-year guidance.

Regarding relative positioning, Terumo exhibits profitability above broad industry quality thresholds, with a 17.4% operating margin, 13.2% net margin, and annualized 9.6% ROE. Its balance sheet retains a strong equity base and conservative 0.48x debt-to-equity ratio, but its relative risk profile has become more acquisition- and working-capital-intensive. The company’s core cardiovascular scale and accelerating Blood and Cell Technologies profitability are strengths, whereas the high inventory days, long cash conversion cycle, and increased intangible-asset concentration distinguish the principal areas requiring execution.